1. Scrip

Shionogi Still Hopeful For Xocova In US Despite Phase III Fail

Missed Primary Endpoints

 
• By Lisa Takagi

Despite sales success in Japan and a fast track designation in the US, Shionogi’s oral COVID-19 therapeutic has missed statistical significance in a global Phase III trial in patients with mild to moderate symptoms.

Shionogi's Xocova faced a thick wall of P3 failure before its NDA filing in the US after a huge commercial success in Japan.
Xocova faces US Phase Phase III failure after commercial success in Japan • Source: Shutterstock

A global Phase III clinical trial with Shionogi & Co. Ltd.’s oral COVID-19 therapeutic Xocova (ensitrelvir) for non-hospitalized patients has missed its primary endpoint, the Japanese firm announced on 13 May.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D